Explore recent issues of Contract Pharma covering key industry trends.
Read the full digital version of our magazine online.
Behind every facility expansion, technology investment, and quality milestone in the CDMO sector is a leadership team making deliberate choices about where to focus, how to grow, and when to take calculated risks.
Stay informed! Subscribe to Contract Pharma for industry news and analysis.
Get the latest updates and breaking news from the pharmaceutical and biopharmaceutical industry.
Discover the newest partnerships and collaborations within the pharma sector.
Keep track of key executive moves and promotions in the pharma and biopharma industry.
Updates on the latest clinical trials and regulatory filings.
Stay informed with the latest financial reports and updates in the pharma industry.
A video roundup of the week’s top industry news stories.
Expert Q&A sessions addressing crucial topics in the pharmaceutical and biopharmaceutical world.
In-depth articles and features covering critical industry developments.
Access exclusive industry insights, interviews, and in-depth analysis.
Insights and analysis from industry experts on current pharma issues.
A one-on-one video interview between our editorial teams and industry leaders.
Listen to expert discussions and interviews in pharma and biopharma.
Contract Pharma Stream offers a centralized destination where users can watch expert-led sessions anytime, anywhere
A detailed look at the leading US players in the global pharmaceutical and BioPharmaceutical industry.
Browse companies involved in pharmaceutical manufacturing and services.
Comprehensive company profiles featuring overviews, key statistics, services, and contact details.
A comprehensive glossary of terms used in the pharmaceutical and biopharmaceutical industry.
Watch in-depth videos featuring industry insights and developments.
Download in-depth eBooks covering various aspects of the pharma industry.
Access detailed whitepapers offering analysis on industry topics.
View and download brochures from companies in the pharmaceutical sector.
Explore content sponsored by industry leaders, providing valuable insights.
Stay updated with the latest press releases from pharma and biopharma companies.
Explore top companies showcasing innovative pharma solutions.
Meet the leaders driving innovation and collaboration.
Engage with sessions and panels on pharma’s key trends.
Hear from experts shaping the pharmaceutical industry.
Join online webinars discussing critical industry topics and trends.
A comprehensive calendar of key industry events around the globe.
Live coverage and updates from major pharma and biopharma shows.
Find advertising opportunities to reach your target audience with Contract Pharma.
Review the editorial standards and guidelines for content published on our site.
Understand how Contract Pharma handles your personal data.
View the terms and conditions for using the Contract Pharma website.
What are you searching for?
How will the Middle Kingdom innovate?
June 8, 2006
By: Tim Wright
Editor-in-Chief, Contract Pharma
Do you remember when Japan was going to take over the world? In the 1980s, that economic powerhouse exemplified all that was wrong with America’s economy, and was poised to dominate world markets in the 21st century. By 1990, its economy fell into recession and it’s been plagued by stagnation and also-ran status ever since. Now it’s China that’s supposed to supplant the U.S. A recent report by PricewaterhouseCoopers contends that the Middle Kingdom will be the world’s largest economy by 2050. While I respect the work that these accountants and analysts do, I have some misgivings over this projection. One is the question of how China is going to handle a rural/poverty-level population that, by itself, is almost three times larger than the entire U.S. population. Another question I have is how the world of 2050 will cope with the environmental damage of China’s (and India’s) rapid industrial development. Still another is the question of how a country can meld totalitarian government with free(ish) markets. China’s regulatory and bureaucratic hurdles are part of the tale behind the country’s history with contract manufacturing, explored in Biopharma CMOs in China, starting on page 110. But my biggest question is whether China will innovate its way out of these problems. For a long time now, I’ve contended that, if any population had an incentive to develop a cheap energy solution, it was the Chinese. It’s a population with plenty of brain power, a clear market demand, and a well-funded government. But we don’t see fuel cells or advanced materials for cheap solar power coming out of China. Instead we see massive oil contract with Sudan and Iran, respectively funding genocide and nuclear weapons programs. China’s government has tried to modernize and privatize business, a process that has led to huge investment from global companies. Most of this investment, however, involves manufacture and re-export to the local market. China may become the biggest economy in the world by 2050, but it will take some doing to become the home to global businesses by then. The country sees its future in being more than a manufacturing platform for these firms, and quite correctly it understands that innovation and home-grown technology is critical to its growth. Which brings me to the story of Chen Jin. Dr. Chen is a scientist, trained in America, who worked at Shanghai’s Jiaotong University to develop new digital signal processing chips, a key component in cell phones. Because foreign companies were afraid of having their IP ripped off in China, they resold DSP chips into the country. Dr. Chen became a national hero when he debuted the Hanxin (China) chip in 2003. Subsequent iterations of the chip, validated as world-class by government testers, showed that China meant business about innovating its way out of its import/export box. Hanxin chips signaled a new dawn. Until it turned out that the chips were a fraud. It turned out that Dr. Chen bought some DSP chips and hired migrant workers to scrub off the word “Motorola” and paint on “Hanxin.” This, as long-time readers can imagine, falls into my “No, seriously” category of anecdotes. Dr. Chen got exposed and denounced, and his funding was recalled. As it turns out, he also has several side businesses, one of which was involved in . . . marketing Hanxin DSP chips to foreign companies! In that sense, China’s business practices seem pretty modern and innovative after all.
Enter the destination URL
Or link to existing content
Enter your account email.
A verification code was sent to your email, Enter the 6-digit code sent to your mail.
Didn't get the code? Check your spam folder or resend code
Set a new password for signing in and accessing your data.
Your Password has been Updated !